U 101 - TCRCure Biopharma
Alternative Names: TC-U101; U-101 - TCRCure BiopharmaLatest Information Update: 10 Apr 2023
Price :
$50 *
At a glance
- Originator TCRCure Biopharma
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Mar 2023 Preclinical trials in Solid tumours in China (Parenteral) prior to March 2023 (TCRCure Biopharma website, March 2023)
- 29 Mar 2023 TCRCure Biopharma plans a phase I trial for Solid tumours (Second-line therapy or greater) (Parenteral) (TCRCure Biopharma website, March 2023)